Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William McLain

Pulmonary Disease Columbia, SC Medical Doctor

NPI 1467426650 CMS profile 201917

700 Gervais St, Suite 200, Columbia, SC 29201

Open in the dashboard

General payments

$3,021

107 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William McLain of Columbia, SC is reported in the CMS Open Payments database as having received $3,021 across 107 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $661 3
2022 General $429 20
2021 General $1,071 41
2020 General $381 21
2019 General $479 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William McLain
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to William McLain were reported at $661. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year William McLain Pulmonary Disease median Middle half National median
2019 $479 $377 $109–$1,340 $163
2020 $381 $230 $56–$907 $114
2021 $1,071 $269 $68–$1,072 $132
2022 $429 $390 $100–$1,457 $149
2023 $0 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $661 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Jazz Pharmaceuticals Inc. $787 38 payments
  2. Eli Lilly and Company $640 2 payments
  3. Harmony Biosciences LLC $304 13 payments
  4. Eisai Inc. $250 8 payments
  5. Arbor Pharmaceuticals, Inc. $214 16 payments
  6. Fisher & Paykel Healthcare Inc $192 5 payments
  7. Inspire Medical Systems, Inc. $135 1 payment
  8. Merck Sharp & Dohme Corporation $115 8 payments
  9. AstraZeneca Pharmaceuticals LP $97 1 payment
  10. Resmed Corp $88 5 payments
  11. Other $200 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,881 105 payments
  2. Education $140 2 payments
Products named General payments · program years 2019–2025
  1. TRULICITY $640 2 payments
  2. SUNOSI $476 19 payments
  3. Wakix $304 13 payments
  4. XYWAV $158 9 payments
  5. Inspire Upper Airway Stimulation System $135 1 payment
  6. Dayvigo $125 7 payments
  7. BELSOMRA $115 8 payments
  8. Horizant $110 8 payments
  9. Obstructive Sleep Apnea Device or Hospital Respiratory Equipment $98 2 payments
  10. BREZTRI $97 1 payment
  11. Other $1,017 48 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

107 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record